Lila Sciences Secures $235M

Lila Sciences, an AI-driven company focused on drug and material discovery, has secured $235 million in funding. The investment, led by Collective Global and Braidwell, will bolster Lila Sciences' efforts to develop novel drugs and materials using artificial intelligence. The company's platform aims to accelerate scientific research by automating experimentation and discovery, combining generative AI with autonomous lab systems to create a closed-loop process. This involves AI generating hypotheses, designing experiments, executing them via robotics, and refining models based on experimental results.

Founded in 2023, Lila Sciences seeks to achieve 'scientific superintelligence' by enabling AI to autonomously manage each step of the scientific method, from idea generation to robotic execution. The company's platform has demonstrated early capabilities, including the discovery of novel antibodies and peptides, and the creation of non-platinum group metals for green hydrogen production. Lila Sciences intends to make its platform available to external partners in the life and materials sciences, with plans to expand its facilities and open new offices.